Navigation Links
Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
Date:12/17/2007

filed as anticipated, this would be our second vaccine IND within 12 months of our first vaccine IND, which we filed in June 2007 for our Pandemic influenza VLP vaccine," said Dr. Rahul Singhvi, Novavax's President and CEO.

About Novavax

Novavax Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding product sales, operating expenses, and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Nova
'/>"/>

SOURCE Novavax, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... CHENGDU, China, Dec. 1 /PRNewswire-Asia-First...mex: TPI ), a manufacturer and supplier of,modern... Chengdu, China, today,announced that it has recei...,Administration (SFDA) to produce Pediatric Fever ... (SFDA approval number Z20093060) and Antibacteria...
(Date:12/1/2009)...VILLE, Md., Dec. 1 Vanda...oday that the waiting period has expired under the...t of 1976 with respect to Vanda,s agreement, dated...at the agreement is now effective. Expiration of ...s of the agreement, triggers an upfront payment to...
(Date:12/1/2009)...DA, Md., Dec. 1 Micromet...ny developing novel, proprietary antibodies for th... diseases today announced that Bayer Schering Phar...ollaboration and license agreement entered into on...or the treatment of solid tumors. ,, Under the ...
Breaking Medicine Technology:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 4Sensing disasters from space 10483 1Sensing disasters from space 10483 2General anesthetics lead to learning disabilities in animal models 59954 1General anesthetics lead to learning disabilities in animal models 59954 2General anesthetics lead to learning disabilities in animal models 59954 3Flu shots not to be sneezed at 59952 1Flu shots not to be sneezed at 59952 2
...aboratory,s Technology Transfer Expertise to Suppo...K, March 30 Biomarkers have become increasingly i...od for risk assessment, early detection, testing n...better drugs once they are developed. As part of ... for Alzheimer,s and other diseases, BARC Central ...
...as now been studied in combination with the most c...10 mg, 20 mg) in patients with mixed dyslipidemia ...y showed that Abbott ,s TRILIPIX(R) (fenofibric a...rosuvastatin calcium met all of the study,s primar...rosuvastatin calcium 5 mg significantly improved H...
Other Medicine Technology:BARC Central Laboratory Joins Alzheimer's Association Research Roundtable 2BARC Central Laboratory Joins Alzheimer's Association Research Roundtable 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5
(Date:12/1/2009)... First Mercury Financial...he "Company") announced today that on November 30,...cash dividend of $0.025 per share, to be paid Dece...se of business on December 15, 2009. ,, Abou... Mercury Financial Corporation provides insurance ...
(Date:12/1/2009)...isolating behaviors jump from friend to friend , ...ew study suggests that lonely people attract fello...too. , "Loneliness can spread from person to pe...n," said James H. Fowler, co-author of the study p...Personality and Social Psychology , and professor ...
(Date:12/1/2009)...s of any medical, legal or business requiring dict...lief this week with the release of ,DictateOnTheGo...r the holiday weekend, allows anyone required to d...ickly and seamlessly using just the iPhone 3G devi... 2009 -- The iPhone App, released by Florida based...
(Date:12/1/2009)... Air Products (NYSE: A...nounced sale of the assets of its polyurethane pre...74; and Versathane® tradenames to COIM USA In...e chemicals producer COIM SpA. ,, Included in ...in Paulsboro, N.J. Terms of the agreement are not ...
(Date:12/1/2009)...wire/ -- Abrazo Media Relations-- The Center for P...pedsorthopaedics.com ) located in Mesa, Arizona an... Hunt Udall to its practice. ,, Dr. Udall is t...after recently completing his fellowship training ...re he focused on adult and pediatric orthopaedic s...
Breaking Medicine News(10 mins):Health News:Loneliness May Be Catching 2Health News:Loneliness May Be Catching 3Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2Health News:Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA 2Health News:Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy 2
...s who live in far-flung areas run a grave risk of ...s, primarily due to an increase in the rates of// ...stated by a report released by The Canadian Instit...ken areas of rural Canada, in striking comparison ...
... Disciplinary Tribunal in New Zealand said that a ...a patient was guilty of professional misconduct.//...plain away his failure by changing medical documen...priate for Dr N to make those additional entries w...
...er of C-section births is partly attributed to the...rities, researchers said. Madonna, Brittany// Spea... for the C-section and this is setting a bad trend...ed by the fact that in our pop culture many celebr...
...that Private clinics who share the status with NHS...nt figures indicate. This responsibility was given...log of waiting lists and to enable better choice t...ned that the clinics are not providing quality ser...
... prostate cancer puts men at increased risk for di...large observational study published in the// Sept....prostate cancer have high five-year survival rates...are policy and of medicine at Harvard Medical Scho...
...edical staffing firm providing healthcare professi...Monday entered into an agreement with// Kochi base...randum of understanding (MoU) was signed between t... The MoU enables InfoVision to commence recruitm...
Other Medicine News:Health News:Rural Canadians, Take Care Of Your Health 2Health News:Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease 2
...the pathologist to visualize the presence of Human...g on a choice of sample types: tissue, monolayer-b... HPV cocktails utilize proprietary probe formulati...to HPV genotypes 16, 18, 31, 33, 35, 39, 51, 52, 5...
Afinion AS100 Analyzer
ID - Candida albicans
AlbiQuick™
Medicine Products: